Browse Clinical Publication Articles by Topic

SGLT2 Inhibitor Plus Aldosterone Antagonist for HFpEF: Safe? Efficacious?

A prospective, open-label, blinded outcome crossover trial of dapagliflozin plus spironolactone vs. dapagliflozin alone in patients with heart failure with preserved or mildly reduced left ventricular ejection fraction resulted in a greater reduction in natriuretic peptides, which was accompanied by a greater decline in kidney function and a rise in serum potassium.

ApoB vs. Lp(a): Which Is More Important for CAD Risk?

In UK Biobank participants without known atherosclerotic cardiovascular disease or diabetes or taking lipid-lowering therapy, the risk of developing coronary artery disease is best determined by apolipoprotein B particle number, but elevated lipoprotein(a) adds significant risk, so both should be considered.

Acute STEMI or Something Else?

Interpret the electrocardiogram (ECG) in the figure without the benefit of any clinical information. Is this ECG indicative of an acute anterior ST-elevation myocardial infarction?

Taletrectinib Capsules (Ibtrozi)

The U.S. Food and Drug Administration has approved a potent, selective, next-generation ROS Proto-Oncogene 1 (ROS1) receptor tyrosine kinase inhibitor, taletrectinib, for the treatment of ROS1-positive non-small cell lung cancer.

Do Gowns Help Prevent Transmission of Respiratory Viruses?

The authors examined various studies to look at the effectiveness of different kinds of gowns and materials in preventing viral infections. The results were mixed, with most studies demonstrating no good evidence that gowning helps in this regard.

Examining Fecal Microbiota Transplant for Primary C. difficile Infection

In a randomized controlled trial conducted in Norway, fecal microbiota transplantation (FMT) was noninferior to vancomycin for the treatment of primary Clostridioides difficile infection, with 66.7% of patients in the FMT group achieving clinical cure without recurrence compared to 61.2% in the vancomycin group over 60 days of follow-up.

Long-Term Peripheral Nerve Function in People with Well-Controlled Type 2 Diabetes

The authors conducted a prospective observational study comparing the effect of early diagnosed, well-controlled type 2 diabetes on peripheral nerve function. Overall, they found similar rates of decline in nerve function in people with well-controlled diabetes compared to age- and sex-matched individuals with normal glucose tolerance. Given the similar decline in nerve function, the authors concluded that the course of diabetic sensorimotor neuropathy is influenced primarily by nerve function at the time of diagnosis and age-related physiological decline.

Semaglutide May Reduce Dementia Risk

In a large nationwide population-based study, semaglutide significantly reduced Alzheimer’s disease-related dementia risk compared to insulin, metformin, and older glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes.

Lenacapavir Injection and Tablets (Yeztugo)

The U.S. Food and Drug Administration has approved lenacapavir, a potent, first-in-class, capsid inhibitor, for reducing the risk of sexually acquired human immunodeficiency virus type 1.

Does Lipoprotein(a) Improve the Risk Calculation of the PREVENT Equation?

A pooled cohort from the Multi-Ethnic Study of Atherosclerosis and the United Kingdom Biobank study has shown that, overall, the American Heart Association PREVENT risk scores performed well at predicting atherosclerotic cardiovascular disease risk even in those with high lipoprotein(a) levels, but considering lipoprotein(a) in those with low PREVENT scores may help make therapeutic decisions in these individuals.